TCGA-86-A4D0-01A-11R-A24H-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 48
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- MYC_TARGETS_V2+0.470
- PANCREAS_BETA_CELLS+0.430
- G2M_CHECKPOINT+0.410
- MYC_TARGETS_V1+0.360
- SPERMATOGENESIS+0.350
- MTORC1_SIGNALING+0.220
- UNFOLDED_PROTEIN_RESPONSE+0.210
- OXIDATIVE_PHOSPHORYLATION+0.200
- BILE_ACID_METABOLISM+0.150
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- TGF_BETA_SIGNALING-0.480
- TNFA_SIGNALING_VIA_NFKB-0.430
- APICAL_JUNCTION-0.420
- APICAL_SURFACE-0.400
- UV_RESPONSE_DN-0.400
- INFLAMMATORY_RESPONSE-0.380
- IL6_JAK_STAT3_SIGNALING-0.370
- P53_PATHWAY-0.370
- INTERFERON_GAMMA_RESPONSE-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-A641-01A-11R-A30B-07 | — | — | 0.901 |
| 2 | TCGA-66-2754-01A-01R-0980-07 | — | cohortA3 | 0.899 |
| 3 | TCGA-37-5819-01A-01R-1635-07 | — | cohortA3 | 0.896 |
| 4 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.891 |
| 5 | TCGA-64-1678-01A-01R-0946-07 | — | cohortA3 | 0.876 |
| 6 | C3L-01285 | — | cohortSQ2 | 0.876 |
| 7 | TCGA-66-2756-01A-01R-0851-07 | — | cohortA3 | 0.875 |
| 8 | TCGA-CV-7418-01A-11R-2081-07 | — | — | 0.872 |
| 9 | TCGA-BA-A4IF-01A-11R-A266-07 | — | — | 0.870 |
| 10 | TCGA-QK-A6VB-01A-12R-A34R-07 | — | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.430 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.090 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.040 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.030 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |